NewLimit raised $435M in Series C funding led by Founders Fund to advance its first age-reprogramming drug into human trials. Post navigation Bitcoin price risks slide to $60K as Iran retaliates against U.S. strikesAI stocks are draining crypto’s momentum, Bitwise warns
